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SPECIAL THEME ARTICLE: OBESITY AND THE RHEUMATIC DISEASES

Glucocorticoid-Related Changes in Body Mass
Index Among Children and Adolescents With
Rheumatic Diseases
NATALIE J. SHIFF,1 ROLLIN BRANT,2 JAIME GUZMAN,2 DAVID A. CABRAL,2 ADAM M. HUBER,3
PAIVI M. MIETTUNEN,4 JOHANNES ROTH,5 ROSIE SCUCCIMARRI,6 NATHALIE ALOS,7
STEPHANIE A. ATKINSON,8 JEAN PAUL COLLET,2 ROBERT COUCH,9 ELIZABETH A. CUMMINGS,3
PETER B. DENT,8 JANET ELLSWORTH,9 JOHN HAY,10 KRISTIN HOUGHTON,2 ROMAN JURENCAK,5
BIANCA LANG,3 MAGGIE LARCHE,8 CLAIRE LEBLANC,6 CELIA RODD,6 CLAIRE SAINT-CYR,7
ROBERT STEIN,11 DAVID STEPHURE,4 SHAYNE TABACK,12 FRANK RAUCH,6 LEANNE M. WARD,5
AND THE CANADIAN STEROID-ASSOCIATED OSTEOPOROSIS IN THE PEDIATRIC POPULATION
CONSORTIUM

Objective. To examine the temporal and dose-related effects of glucocorticoids (GCs) on body mass index (BMI) in
children with rheumatic diseases.
Methods. Children initiating GCs for a rheumatic disease (n ⴝ 130) were assessed every 3 months for 18 months. BMI,
weight, and height Z score trajectories were described according to GC starting dosage in prednisone equivalents: high
(>1.0 mg/kg/day), low (<0.2 mg/kg/day to a maximum of 7.5 mg/day), and moderate (between high and low) dosage. The
impact of GC dosing, underlying diagnosis, pubertal status, physical activity, and disease activity on BMI Z scores and
on percent body fat was assessed with longitudinal mixed-effects growth curve models.
Results. The GC starting dose was high in 59% and moderate in 39% of patients. The peak BMI Z score was ⴙ1.29 at 4
months with high-dose GCs and ⴙ0.69 at 4.2 months with moderate-dose GCs (P < 0.001). Overall, 50% (95% conﬁdence
interval 41–59%) of the children returned to within ⴙ0.25 SD of their baseline BMI Z score. Oral GC dose over the
preceding 3 months was the most signiﬁcant determinant of BMI Z score and percent body fat. The proportion of days in
receipt of GCs, disease activity, and a diagnosis of systemic-onset juvenile idiopathic arthritis were also associated with
BMI Z scores. The correlation between changes in BMI and changes in percent body fat was 0.09.
Conclusion. In children with rheumatic diseases starting moderate and high doses of GCs, BMI Z scores peaked at 4
months, and only half returned to within ⴙ0.25 SD of their baseline BMI Z score after 18 months.

INTRODUCTION
Glucocorticoids (GCs) commonly used for the treatment of
children with rheumatic diseases can cause weight gain
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that is distressing to patients (1,2) and their families. It is
not known how many children restore their premorbid
weight after discontinuing or reducing GC therapy. The
risks associated with non–GC-related obesity in pediatric
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Signiﬁcance & Innovations
●

This is the ﬁrst study to prospectively describe
how body mass index (BMI), height, and weight Z
scores change over time after glucocorticoid (GC)
initiation for pediatric rheumatic disease.

●

After peaking at 4 months, only half of the children returned to their baseline BMI Z scores by 18
months.

●

Oral GC dose was the most signiﬁcant determinant
of BMI gain after adjusting for physical activity,
diagnosis, disease activity, baseline BMI Z scores,
pubertal status, age, sex, intravenous GCs, and
days in receipt of GCs.

●

Changes in BMI correlated poorly with changes in
percent body fat among GC-treated children with
rheumatic disease.

6 patients had an initial BMI greater than the 75th percentile (reanalysis of data from reference 18).
Physical activity is an important aspect of healthy
weight maintenance and potentially could impact the effect of GCs on BMI changes; however, the aerobic and
anaerobic exercise capacity in children and adolescents
with JIA is signiﬁcantly impaired compared to healthy
controls, and those with more swollen joints tend to be
less physically active (19). Reduced ﬁtness may persist
even when the disease is in remission (20 –22).
In the present study, we sought to describe the changes
in BMI Z scores during the 18 months following initiation
of GCs among children with rheumatic diseases. We further aimed to determine the proportion of children who
had a return of their BMI Z score to the baseline level, and
to assess the inﬂuence of the mean daily GC dose, days in
receipt of GCs, disease type, and physical and disease
activity on BMI Z scores.

PATIENTS AND METHODS
patients (3,4) include metabolic syndrome (5), increased
arterial stiffness (6), advanced vascular age (7), increased
left atrial size (8), increased risk of coronary artery disease
(9,10), and type 2 diabetes mellitus (11). Adolescent obesity frequently tracks into adulthood (12), and there are
known obesity-associated health risks at all ages (13–16).
Conversely, obese children who reduce weight can lower
the associated health risks (17).
Childhood rheumatic diseases that may require GC treatment include juvenile idiopathic arthritis (JIA), particularly the systemic subtype of JIA; systemic lupus erythematosus (SLE); juvenile dermatomyositis (DM); chronic
systemic vasculitis (CSV); and others. GCs are often prescribed in moderate to large doses for rapid control of
inﬂammation, with subsequent tapering and ideally discontinuation if disease activity is controlled with treatment using other medications. There is a paucity of studies
in the literature to guide practitioners in counseling children about anticipated weight changes following GC initiation. The only study examining body mass index (BMI)
changes in pediatric rheumatic diseases to date included
15 children receiving high-dose GCs. In this study, BMI
percentiles increased 6 – 8 weeks after starting GCs and
peaked at 6 –9 months (18). Our reanalysis of data from the
Tekano et al study (18) showed that 6 children had a BMI
consistently above the 85th percentile at 24 months; these
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We used data from the Steroid-Associated Osteoporosis in
the Pediatric Population (STOPP) study (members of the
Canadian STOPP Consortium are shown in Appendix A).
This prospective observational study involving 10 Canadian academic pediatric centers was principally designed
to study bone health among children with GC-treated disorders. Details of the STOPP protocol for children initiating GC therapy for rheumatic diseases have been published previously (23,24).
Patient population. All children in the STOPP study
receiving GCs for the treatment of a rheumatic disease with
at least 1 followup visit were eligible for this study if they
were ⱕ16 years of age at enrollment and had a ﬁrst-time
requirement for intravenous or oral GC therapy as determined by their pediatric rheumatologist. The eligibility
criteria for enrollment in the STOPP study have been
described in detail elsewhere (24). Children were excluded from the study if they had previously taken GCs for
the treatment of the underlying disease. Patients were also
excluded if they had received intravenous or oral GCs for
⬎14 consecutive days in the 12 months preceding study
enrollment to treat any other medical condition (e.g.,
asthma) or if they had had complete immobilization for
⬎14 consecutive days prior to enrollment. The children
were studied every 3 months for 1 year to allow for accurate collection of the clinical data. The research ethics
boards of each participating institution approved the study
and informed consent/assent was obtained prior to enrollment.
Data collection. The baseline visit was targeted within
30 days of GC initiation. Height and weight were measured
using standardized procedures, as previously described
(25). BMI was calculated as weight in kilograms divided by
the square of the height in meters, and BMI Z scores were
generated using the Centers for Disease Control and Prevention reference values (26) available in Stata software.
Since these BMI Z scores are only available for children
ⱖ2 years of age, data for patients ⬍2 years old at enroll-
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ment were included in the graphical trajectories after their
second birthday, but were excluded from the mixed-effects
models and were not analyzed for return to baseline BMI Z
scores. The Habitual Activity Estimation Scale (HAES)
was used to measure physical activity (27,28), and rheumatic disease activity was assessed with a 10-cm visual
analog scale (VAS) by the treating rheumatologist (29).
Puberty was assessed by physical examination according
to the Marshall and Tanner method (30,31) at baseline and
at 12 months, except for one study center where it was
recorded by self-report (32). Body composition was evaluated at baseline and every 6 months by dual x-ray absorptiometry (DXA). Patients with JIA who received GC therapy for ⬍4 months underwent annual DXA scans (rather
than DXA scans every 6 months) after the ﬁrst year of the
study.
GC dosing. GC dosing was determined entirely at the
discretion of the treating rheumatologist. Daily GC doses
and changes were documented at followup by a chart
review, patient or parent interview, and review of patient
home GC diaries. When a patient missed a study visit, a
research assistant called the family by telephone to record
GC dose changes. GC doses were converted to mg/kg/day
of prednisone equivalents.
Due to the paucity of available information on GC-related BMI changes, a focus group comprised of pediatric
rheumatologists and allied health professionals convened
to determine an a priori clinically meaningful framework
to describe the GC dosing. The focus group members recommended an analysis based on the initial GC dose, since
this information coincides with what information is available at the time patients are counseled about the potential
for GC-related weight gain; this is analogous to an intentto-treat analysis. The starting dose was calculated as the
mean daily combined intravenous and oral dose during
the ﬁrst 2 weeks of therapy. A high starting dosage was
deﬁned as ⱖ1.0 mg/kg/day of prednisone equivalents
(33,34), a low dosage as ⬍0.2 mg/kg/day to a maximum of
7.5 mg/day (35), and a moderate dose as any dose in
between.
GC exposure between each 3-month study visit was
described in the analysis as follows: 1) the mean daily oral
GC dosage (mg/kg/day), 2) the mean daily intravenous GC
dosage (mg/kg/day), and 3) the proportion of days in receipt of GCs (the number of days in receipt of GCs between
study visits divided by the number of days between study
visits). The weight used to calculate the mean daily oral
and intravenous doses was estimated each day during the
study period by a simple linear interpolation of the
weights from the study visit data; this allowed the analyses
to separately account for the route, dose, and number of
days treated with GCs. Once-daily dosing and divided
daily dosing were not distinguished in the models because
information on divided daily dosing was not available.
Physical activity. The HAES is a validated measure of
daily physical activity in children (27,28) that has been
used in multiple pediatric settings (36 –38). Parents completed the HAES for children ages ⬍13 years, and when

115
possible, children ages ⱖ13 years completed the scale
themselves. The HAES measures the amount of physical
activity over the preceding week and provides the duration of time spent in each of 4 levels of intensity (inactive,
somewhat inactive, somewhat active, and very active) for
an awake day. Visits with ⬎90% of awake time spent
doing physical activity were removed from the analysis as
incorrectly completed questionnaires.
Disease activity. Disease activity was scored on a 10-cm
VAS by a pediatric rheumatologist (29), where 0 cm ⫽
inactive disease and 10 cm ⫽ very active disease. The scale
refers to the particular disease being scored. Differences
across diseases in VAS scoring and effects on BMI (39)
were accounted for in statistical modeling by adding variables for the 5 groups of diseases: juvenile DM, SLE, systemiconset JIA, CSV, and other rheumatic diseases. CSV included
Takayasu arteritis, granulomatosis with polyangiitis (Wegener’s), microscopic polyangiitis, perinuclear antineutrophil cytoplasmic antibody (pANCA)–positive renal limited vasculitis, and pANCA-positive vasculitis with
Goodpasture’s syndrome. This statistical model allowed
for the estimation of the interactions between GC dose and
disease groups.
Body composition by DXA. Body composition was measured every 6 months with DXA using either QDR 4500
(Hologic) at 3 centers, Discovery (Hologic) at 2 centers, and
Delphi (Hologic) at 1 center, or Lunar Prodigy (GE Medical
Systems) at 4 centers. These instruments were cross calibrated for bone mineral content in the spine, but not for
percent body fat data. The within-subject changes in percent body fat could therefore be modeled, but not betweensubject differences, since between-subject differences
would have been at least partially attributable to different
machines. Percent body fat was calculated as the number
of grams of fat divided by grams of total body weight (the
sum of fat mass, lean mass, and bone mineral content
determined from the DXA scan).
Statistical analysis. We described BMI, weight, and
height Z score trajectories graphically by ﬁtting splines in
time from study entry using a longitudinal mixed-effects
model. The degree of complexity for the spline representations was chosen based on Akaike’s information criterion (AIC) values, which indicated that 4 df were sufﬁcient
to accurately capture the underlying functional form of the
relationship. We deﬁned return-to-baseline BMI as a return to within 0.25 SD above the baseline BMI Z scores.
The models for growth were based on annualized, between-visit growth rates (change in growth parameter between visits divided by the time in years between visits).
To allow for variation in growth rates due to age and sex,
we applied linear mixed-effects models with a spline term
for age and an interaction with sex. These terms were
reduced to additive linear terms in age and sex based on
estimated predictive accuracy of the models, as indicated
by AIC values.
We used mixed-effects multiple regression models to
estimate the impact of a number of factors on BMI Z scores.
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Table 1. Baseline patient characteristics (n ⴝ 130)*
Baseline characteristics

Result

Age, median (IQR) years
Female
Some white ethnicity†
Days after diagnosis at enrollment, median (IQR)
GC starting dosage, median (IQR) mg/kg/day
Low
Moderate
High
Days in receipt of GCs between study visits, median (IQR) %
All patients
Low starting dose group
Moderate starting dose group
High starting dose group
Patients in each GC group‡
Low
Moderate
High
Diagnosis‡
Juvenile idiopathic arthritis (all subtypes)
Systemic arthritis
Polyarthritis, rheumatoid factor negative
Polyarthritis, rheumatoid factor positive
Enthesitis-related arthritis
Oligoarticular arthritis
Psoriatic arthritis
Unclassiﬁed
Juvenile dermatomyositis
Systemic lupus erythematosus
Localized scleroderma
Systemic scleroderma
Overlap syndromes (including mixed connective tissue disease)
Chronic systemic vasculitis§
CNS vasculitis

9.8 (5.9–13.8)
86 (66)
101 (78)
24 (15–24)
0.09 (0.07–0.10)
0.50 (0.35–0.70)
3.60 (1.60–8.00)
74 (37–100)
5 (0.2–20)
66 (20–96)
81 (46–100)
4 (3)
50 (39)
76 (59)
49 (38)
24 (18)
8 (6)
5 (4)
3 (2)
3 (2)
2 (2)
4 (3)
30 (23)
20 (15)
10 (8)
1 (1)
5 (4)
14 (11)
1 (1)

* Values are the number (percentage) unless otherwise indicated. IQR ⫽ interquartile range; GC ⫽
glucocorticoid; CNS ⫽ central nervous system.
† Includes all patients with any amount of white ethnicity.
‡ Total is 101% due to rounding.
§ Includes Takayasu arteritis, granulomatosis with polyangiitis (Wegener’s), microscopic polyangiitis,
perinuclear antineutrophil cytoplasmic antibody (pANCA)–positive renal limited vasculitis, and
pANCA-positive vasculitis with Goodpasture’s syndrome.

The between-subject variation in growth rate and sensitivity to GC dose were incorporated as random effects. Covariates representing baseline BMI Z score, pubertal status,
physical activity, and underlying rheumatic disease were
included. Time-dependent covariates in the preceding 3
months included the mean daily oral GC dosage between
each study visit (mg/kg/day), mean daily intravenous GC
dosage between each study visit (mg/kg/day), proportion
of days between study visits in receipt of GCs, and disease
activity. There were no interactions between GC dose and
disease groups in this model.
The disease activity between study visits was calculated
by averaging the VAS scores at each study visit with the
VAS scores at the previous study visit to reﬂect the mean
disease activity in the preceding 3-month interval. The
reference category for disease type was juvenile DM. Tanner growth stages were categorized as early puberty (Tanner stages 1–2) or mid- to late puberty (Tanner stages 3–5)
(40). Patients were then divided into 3 groups (early puberty at baseline and 12 months, mid- to late puberty at

both assessments, and early puberty at baseline but mid- to
late puberty at 12 months). The combined inactive and
somewhat active hours in the week prior to each study
visit as recorded by the HAES were included in the BMI Z
score and DXA percent body fat models, since these were
deemed to be the most relevant measures for the models.
Statistical signiﬁcance was set at a P value less than 0.05.
Percent body fat mass trajectories were modeled similarly to BMI Z score curves while controlling for height,
age, and sex, which are known potential confounders.
Independent variables included interval-speciﬁc mean
daily oral GC dose, interval-speciﬁc mean daily intravenous GC dose, interval-speciﬁc proportion of days in receipt of GCs, physical activity, pubertal status, type of
rheumatic disease, and disease activity. We did not control
for baseline fat mass because we modeled changes from
baseline and not absolute values. The correlation between
percent body fat mass and BMI changes was described
using Pearson’s correlation coefﬁcient. R was used for all
analyses (41).

BMI and Glucocorticoids in Children With Rheumatic Diseases

Figure 1. Box plot of glucocorticoid doses at each study visit over
the 18-month study period, during which the doses steadily decreased. The lines inside the boxes represent the median dose at
each visit. The circles indicate outliers.

RESULTS
The 130 eligible patients (96% of the total cohort [n ⫽
136]) had a mean age of 9.8 years and were predominantly
female (66%). Six patients were excluded; 2 did not have
a well-established rheumatic disease and 4 were excluded
for a lack of followup. Percent body fat mass was available
for 127 of the 130 patients. At baseline, 16% of the patients
had a BMI greater than the 85th percentile and 13% had a
BMI greater than the 95th percentile, while at 18 months,
these percentages were 24% and 16%, respectively. Additional baseline characteristics are shown in Table 1. GC
dosing over the 18 months varied signiﬁcantly among the
children, in accordance with the treatment decisions made
by the attending rheumatologists based on disease manifestations. By 6 months, 22% had discontinued GCs, and
by 12 months, 31% had discontinued GCs. In addition,
62% received GCs longer than 12 months, and 7% received GCs for ⱖ2 discrete periods separated by a minimum 6-week GC-free interval. The median starting GC
dosage was 1.3 mg/kg/day of prednisone equivalents. Figure 1 shows the dosing pattern over time. Overall, 37% of
the children were still receiving GCs within 2 weeks of the
18-month visit, at which time their median GC dosage was
0.37 mg/kg/day. Only 1 of the 4 patients in the low starting
dose group and 5 of the 50 patients in the moderate starting dose group received intravenous pulse therapy at any
point in the study.
The GC starting dose was high in 59% of the patients,
moderate in 39%, and low in 3% (the total is 101% because of rounding). BMI peaked at 4.0 months in the highdose group and 4.2 months in the moderate-dose group;
the curves of mean BMI Z scores over time differed significantly for the moderate- and high-dose GC groups (P ⬍
0.001) (Figure 2). The mean peak BMI Z scores were 1.29
and 0.69 in the high- and moderate-dose groups, respectively. The low starting dose group was not analyzed
graphically because it included only 4 children; however,
this group was included in the longitudinal modeling.
Despite the high level of signiﬁcance, the R2 values of the
graphical models shown in Figure 2 were low at 0.05 for
the moderate starting dose group and 0.02 for the high
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starting dose group, indicating that these models have
limited predictive ability for individual patients.
Data for the assessment of a return to the baseline BMI Z
scores were available for 112 (86%) of the 130 children. At
18 months, 50% (95% conﬁdence interval 41–59%) of the
subjects failed to return to their baseline BMI Z scores, and
there was no difference between the moderate (48%) and
high (52%) GC starting dose groups. Overall, 30% of the
patients who returned to baseline BMI Z scores and 45% of
patients who did not were still being treated with GCs
within 2 weeks of their 18-month visit (P ⫽ 0.17), while
70% of the patients who returned to baseline BMI Z scores
had stopped taking GCs. The estimated mean height Z
scores declined with GC therapy and did not recover during the study period, while the mean weight Z score trajectories tended to parallel the trajectories of the BMI Z
scores (Figure 3). The mean BMI and weight Z scores
differed signiﬁcantly between the moderate- and highdose groups (P ⬍ 0.0001), whereas mean height Z scores
did not.
In mixed-effects modeling, after controlling for intravenous GC dose, baseline raw BMI, sex, pubertal status,
physical activity, and rheumatic disease, the only signiﬁcant predictors of BMI Z scores were oral GC dose, proportion of days in receipt of GCs, disease activity, and the
presence of systemic-onset JIA (Table 2). The longitudinal
model used the mean daily dosage of prednisone equivalents in mg/kg/day in the previous 3-month study interval
to predict the BMI Z scores at each 3-month study visit.
Age was signiﬁcant when the model did not adjust for
pubertal status (data not shown). All patients were included in the longitudinal model irrespective of their starting dose.
The correlation between raw BMI results (not BMI Z
scores) and body fat at baseline was 0.75, and at 6 months
the correlation was 0.78; however, the correlation between
the change in raw BMI results and the change in percent
body fat from baseline to 6 months after initiation of GCs
was quite low at 0.09. Similar to the BMI Z score model,
the mean daily oral GC dose (25.75, SE 3.10, P ⬍ 0.00) and

Figure 2. Body mass index (BMI) Z score trajectories and 95%
conﬁdence intervals for children with rheumatic disease according to the glucocorticoid (GC) starting dose (n ⫽ 126). GC starting
dosages were deﬁned as high (ⱖ1.00 mg/kg/day) for 76 children
and moderate for 50 children. The y-axis shows actual BMI Z
scores. BMI Z scores start close to 0 because our population had a
relatively normal BMI distribution at enrollment.
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moderate- and high-dose GCs, as expected, but the degree
of variability in the data was quite large. Therefore, these
trajectories provided a clear picture of population-level
data, but were of limited value for individual patient predictions.
Larger BMI Z scores were associated with a combination
of height deﬁcits and increased weight. Although decreased height Z scores may have partially explained the
initial increases in BMI Z scores, after BMI Z score trajectories peaked, they returned toward their baseline values
and diverged from height Z scores trajectories, while the
height Z score trajectories showed continued height deﬁcits. The weight Z score curves paralleled the BMI Z score
trajectories more closely, indicating that increased weight,
and not just height deﬁcits, was responsible for the shape
of the BMI trajectories.
A widely held belief based on long-term clinical experience is that alternate day steroids are less lipogenic than
Table 2. Regression coefﬁcients for mixed-effects
modeling of BMI Z scores for 18 months after GC
therapy was started (n ⴝ 112)*

Figure 3. Weight and height Z score trajectories and 95% conﬁdence intervals for children with rheumatic disease according to
the glucocorticoid starting dose.

proportion of days in receipt of GCs (⫺5.21, SE 1.79, P ⬍
0.00) had signiﬁcant effects on changes in percent body fat,
although in this model the disease group termed other was
also signiﬁcant (4.64, SE 1.69, P ⫽ 0.01) when controlling
for age, height, sex, mean daily intravenous GC dose, pubertal status, disease type, disease activity, and physical
activity. Although lean body mass generally increased following GC initiation, there was an abundance of variability in this parameter. In the raw data, fat mass appeared to
contribute more to increases in mass than lean body mass,
resulting in a relative decrease in the percent lean body
mass (data not shown).

DISCUSSION
The prospective longitudinal tracking of changes in BMI Z
scores over the 18-month period after starting GCs for
GC-naive children with rheumatic diseases showed that
BMI Z scores peaked at 4 months, with a mean peak Z
score of 1.3 in those starting high-dose GCs and 0.7 in
those starting moderate-dose GCs. Half of these children
did not return to their baseline BMI Z score by 18 months,
and this failure to return to baseline values was equally
likely in patients in the moderate and high GC starting
dose groups. Oral GC dose, proportion of days in receipt of
GCs, and disease activity signiﬁcantly predicted BMI Z
scores. Although observations were limited to 3-month
intervals, peak BMI Z scores occurred sooner than we had
predicted from pilot data (18), while physical activity,
disease type, and disease activity had minimal impact on
BMI Z score trajectories, in keeping with our a priori
hypothesis. The graphical mean trajectories of BMI Z
scores signiﬁcantly differed between children initiating

Variable
Oral GCs, mg/kg/day†
Intravenous GCs, mg/kg/day†
Proportion of days in receipt
of GCs‡
Male§
Age, years
Inactive HAES score¶
Entered puberty#
Postpubertal at baseline**
SLE††
Systemic-onset JIA††
CSV‡‡
Other rheumatic disease††
Disease activity§§
Baseline raw BMI

Coefﬁcient
(SE)

P

4.29 (0.45)
0.38 (0.25)
⫺0.98 (0.22)

⬍ 0.00
0.12
⬍ 0.00

⫺0.35 (0.19)
0.05 (0.04)
0.01 (0.01)
0.22 (0.62)
0.06 (0.29)
0.17 (0.31)
0.57 (0.28)
⫺0.22 (0.31)
0.44 (0.02)
0.15 (0.05)
0.04 (0.02)

0.06
0.19
0.68
0.72
0.83
0.59
0.04
0.48
0.08
⬍ 0.00
0.05

* Coefﬁcients show the effect over 1 year and can be divided to
show the effect over shorter time intervals. For example, dividing
coefﬁcients in half would show the effect over a 6-month period.
BMI ⫽ body mass index; GC ⫽ glucocorticoid; HAES ⫽ Habitual
Activity Estimation Scale; SLE ⫽ systemic lupus erythematosus;
JIA ⫽ juvenile idiopathic arthritis; CSV ⫽ chronic systemic vasculitis.
† Mean daily dosage during the preceding 3-month interval.
‡ Proportion of days in receipt of GCs during the preceding 3-month
interval.
§ Compared to female.
¶ The inactive component of the HAES (sum of somewhat inactive
and inactive hours).
# Entered puberty sometime during the 18-month study period.
Compared to remaining prepubertal throughout the 18-month study
period.
** Compared to remaining prepubertal throughout the 18-month
study period.
†† Juvenile dermatomyositis was the reference category for all disease groups.
‡‡ Juvenile dermatomyositis was the reference category for all disease groups. CSV includes Takayasu arteritis, granulomatosis with
polyangiitis (Wegener’s), microscopic polyangiitis, perinuclear antineutrophil cytoplasmic antibody (pANCA)–positive renal limited
vasculitis, and pANCA-positive vasculitis with Goodpasture’s syndrome.
§§ Disease activity reﬂects the average activity during the preceding
3-month interval.
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daily steroids. Surprisingly, once accounting for all covariates, including GC dose and route of administration, an
increased proportion of days in receipt of GCs was associated with a smaller increase in BMI. In our model (while
maintaining all other variables constant), for the same
average daily GC dose regardless of whether the doses
were administered orally or intravenously, each 10% increase in the proportion of days in receipt of GCs reduced
the BMI Z score by 0.1 unit over the course of a year. One
explanation for this could be that large, intermittent GC
pulses may have different and longer-lasting effects than
alternate day lower-dose oral GCs; however, our model
could not test this possibility. Our ﬁndings may also be a
result of reverse causation, whereby the physicians decreased the GC dose or changed the route of administration
when there was a large increase in BMI.
The relationships between obesity and GC therapy in the
treatment of children with other chronic pediatric diseases
have been described, but because of the disease-speciﬁc
variation in GC dosing strategies, it is difﬁcult to extrapolate these ﬁndings to children with chronic rheumatic
diseases. However, GC-induced obesity has been reported
to occur in 35– 41% of children with nephrotic syndrome,
although the extent to which their obesity resolved was
not clearly described (42– 44).
To our knowledge, there are no published studies examining the degree to which physical activity impacts GC-associated weight changes. In our study, physical activity did not
attenuate the GC-associated increase in BMI. Additionally,
disease activity assessed by the treating physician did not
signiﬁcantly impact the BMI trajectories in our models.
Although BMI is easily obtained, it does not always
reﬂect percent body fat (45), whereas DXA is a direct
measure of adiposity. In this study, the within-subject
changes in raw BMI did not correlate with changes in
percent body fat, even when accounting for height, age,
and sex as potential confounders. Changes in percent body
fat are small relative to absolute values; therefore, the
relative error in these changes is much larger than the
relative error for the absolute values, which may partially
explain the poor correlation between the changes in BMI
and percent body fat. Previous ﬁndings from small studies
have suggested that there is a discrepancy between BMI
measurements and percent body fat (46) and a higher
percent body fat (47) in patients with a history of a pediatric rheumatic disease compared to controls.
A number of limitations to this study could threaten the
generalizability of our ﬁndings. The requirement of study
visits every 3 months potentially precluded the participation of patients who were not able to meet the STOPP
study demands. Furthermore, participants were enrolled
from tertiary care pediatric centers, where the majority of
Canadian pediatric rheumatologists practice; conversely,
the number of children with rheumatic diseases undergoing care solely outside of these centers is likely very small.
Our study ﬁndings may not be generalizable to non-Canadian settings where health care access is not universal or
where physicians other than pediatric rheumatologists
provide care for these patients, since these physicians may
have a different approach to GC prescription. Additionally, although we considered modeling the World Health
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Organization BMI Z scores, when we examined the baseline distribution of these BMI Z scores in our population,
the large number of outliers present indicated that these
BMI curves did not reﬂect our population as well as the
Centers for Disease Control and Prevention BMI curves.
Furthermore, indirect measures of physical activity, such
as the one we used, tend to overestimate physical activity
when compared to direct measures (48). Finally, data on
changes in caloric intake were not collected in this study.
GC-induced weight gain is a distressing side effect of
therapy for children and youth with rheumatic diseases
(1). This study provides data from a relatively large cohort
of children and adolescents with rheumatic diseases initiating GC therapy for the ﬁrst time for their rheumatic
disease. It describes how much and how soon BMI Z
scores increase, to what extent BMI Z scores are restored
to the previous status over 18 months, and how these
changes relate to the GC starting dose. The observed BMI Z
score trajectories will help health care providers to counsel children with rheumatic diseases and their families
about the expected timing and degree of GC-induced BMI
changes at a population level, although the BMI trajectories cannot be used for predictions at an individual level.
Further work is necessary to clarify BMI changes beyond
18 months after GC initiation. Our surprising ﬁnding, that
increased days in receipt of GCs was associated with a
smaller increase in BMI Z scores, requires additional evaluation.
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